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ABSTRACT
 
Purpose: To identify incidence and predictors of stress urinary incontinence (SUI) 
following Holmium laser enucleation of the prostate (HoLEP).
Materials and Methods: We performed a retrospective review of 589 HoLEP patients 
from 2012-2018. Patients were assessed at pre-operative and post-operative visits. 
Univariate and multivariate regression analyses were performed to identify predictors 
of SUI.
Results: 52/589 patients (8.8%) developed transient SUI, while 9/589 (1.5%) developed 
long-term SUI. tSUI resolved for 46 patients (88.5%) within the first six weeks and 
in 6 patients (11.5%) between 6 weeks to 3 months. Long-term SUI patients required 
intervention, achieving continence at 16.4 months on average, 44 men (70.9%) with 
incontinence were catheter dependent preoperatively. Mean prostatic volume was 
148.7mL in tSUI patients, 111.6mL in long-term SUI, and 87.9mL in others (p <0.0001). 
On univariate analysis, laser energy used (p <0.0001), laser “on” time (p=0.0204), 
resected prostate weight (p <0.0001), overall International Prostate Symptom Score 
(IPSS) (p=0.0005), and IPSS QOL (p=0.02) were associated with SUI. On multivariate 
analysis, resected prostate weight was predictive of any SUI and tSUI, with no risk 
factors identified for long-term SUI.
Conclusion: Post-HoLEP SUI occurs in ~10% of patients, with 1.5% continuing beyond 
six months. Most patients with tSUI recover within the first six weeks. Prostate size 
>100g and catheter dependency are associated with increased risk tSUI. Larger prostate 
volume is an independent predictor of any SUI, and tSUI.
ARTICLE INFO 
 Seth Teplitsky
http://orcid.org/0000-0001-9242-1360
Keywords:
Epidemiology; physiopathology 
[Subheading]; Urinary 
Incontinence
Int Braz J Urol. 2020; 46: 624-31
_____________________
Submitted for publication:
June 22, 2019
_____________________
Accepted after revision:
August 30, 2019
_____________________
Published as Ahead of Print:
March 25, 2020
INTRODUCTION
Benign prostatic hyperplasia (BPH) is a 
common condition affecting many older men. 
In the United States, more than 70% of men 
aged 60-69 years have symptoms associated 
with BPH. Currently, lower urinary tract symp-
toms (LUTS) impact almost 80% of men older 
than 70 (1).
 Historically, transurethral resection of the 
prostate (TURP) has been the gold standard for 
endoscopic management of BPH (2). This techni-
que, although effective, has many potential ad-
verse effects and limitations which have prompted 
the advent of newer treatment modalities for BPH 
(3-5). Holmium-laser enucleation of the prosta-
te (HoLEP) is one of the most prominent newer 
modalities. HoLEP is size independent and can be 
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used for enucleation of prostates over 100g, which 
has traditionally been a limitation of TURP. Re-
cent studies have shown that HoLEP is equally 
as effective, and potentially more effective, when 
compared to TURP and open simple prostatectomy 
across a variety of outcomes (4).
 With HoLEP now recognized in the AUA 
guidelines as a viable alternative treatment op-
tion for those with moderate to severe LUTS, it is 
important to understand better the adverse event 
profile associated with this procedure (6). In our 
institutional experience, the most common com-
plication encountered with HoLEP is postoperative 
stress urinary incontinence (SUI). The vast majority 
of SUI seen after HoLEP is transient, with the majo-
rity of cases resolving within one year (7). We have 
found that transient SUI (tSUI) represents one of the 
most common complaints affecting patient satisfac-
tion and the quality of life postoperatively. Recent 
reports note that the rates of postoperative SUI 
range between 1.4% and 44% following HoLEP 
(8-11). The wide range in reported SUI rates is 
most likely multifactorial and may be due to di-
fferent operative techniques, surgeon experience, 
and patient-specific factors. Unfortunately, many 
of these studies are limited by small sample sizes 
and technique heterogeneity.
 With this study, we aim to more accura-
tely define SUI rates using a large single-surgeon 
single-institutional experience and to identify the 
incidence and predictors of SUI following HoLEP. 
With this knowledge, surgeons can better coun-
sel patients regarding the procedure allowing for 
more informed patient decision making and im-
prove patient satisfaction.
MATERIALS AND METHODS
 We performed an IRB approved (Control 
#12D.50) retrospective chart review of all patients 
undergoing HoLEP at our institution between Janu-
ary 2012 and June 2018. Our review included the 
charts of all patient who underwent HoLEP at our 
institution within this time period under the care of 
a single surgeon. The exclusion criteria for this re-
view include incomplete surgical resection and lack 
of post-operative follow-up. Baseline demographic 
data collected included age, body mass index (BMI), 
serum prostate-specific antigen (PSA), prostate vo-
lume, peak Uroflow rate, mean Uroflow rate, PVR 
volume, IPSS score, and IPSS QOL rating. All pa-
tients underwent urodynamic testing (Laborie Me-
dical Technologies®) before undergoing surgery to 
confirm the diagnosis of bladder outlet obstruction. 
All procedures were performed by a single experien-
ced surgeon (A.D.) who had performed more than 
one thousand HoLEP cases before the study period. 
Postoperative clinic visits were conducted within 
two weeks, at six weeks, and at three months. As-
sessment at postoperative visits included the IPSS 
questionnaire, PVR, and Uroflow testing.
 Our trilobar HoLEP technique has been des-
cribed previously, but in brief, a 26 French (Fr) conti-
nuous flow resectoscope with a laser bridge adapter 
and an endoscopic camera are utilized (12). The laser 
fiber is passed through a 6Fr open-ended ureteral 
catheter. A 100 Watt holmium laser with an end-
-firing 550-micron laser fiber is used with energy 
settings of 2.0J and 50Hz. After trilobar enucleation 
is completed, a morcellator, grasper, or both are used 
to clear the bladder of any prostatic tissue.
 At postoperative visits, SUI was assessed 
clinically, which was defined as incontinence du-
ring activity with a patient-reported negative im-
pact on quality of life. Any patient who reported 
incontinence which necessitated the utilization 
of undergarment pads or diapers was considered 
“incontinence”, while those who did not report 
needing any pads or diapers were considered con-
tinent for our study purposes. SUI was differentia-
ted from other forms of incontinence by careful 
history taking and physical examination in the 
clinic. Patients with different types of incontinen-
ce, such as urge or mixed, were excluded from 
this study. For study purposes, SUI was considered 
transient if it resolved within six months of the 
procedure date, in following with previous lite-
rature (6). Any leakage beyond six months was 
deemed to be long-term SUI.
 Additional risk factors assessed inclu-
ded prostate size as measured by TRUS, CT, or 
MRI imaging. Patients were risk stratified based 
on preoperative prostate size (>100g or ≤100g) 
and pre-operative catheter dependency status 
(clean intermittent catheterization and conti-
nuous urethral drainage).
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 Univariate analysis for baseline demogra-
phics and perioperative risk factors were completed 
using the chi-square test for categorical variables 
and ANOVA for comparison of continuous varia-
bles. Multivariable logistic regression was comple-
ted to identify factors predictive of increased risk for 
any SUI, transient SUI, and long-term SUI after Ho-
LEP. Significant factors from the univariate analysis 
were included in the multivariable analysis. Analy-
ses were completed using SPSS®, version 23.0.
RESULTS
 Five hundred eighty nine men under-
going HoLEP during the study period were 
identified. Postoperative tSUI occurred in 52 
men (8.8%), while 9 (1.5%) had long-term SUI, 
for a total of 61 (10.4%) patients who experien-
ced any SUI after HoLEP. Of the patients who 
experienced tSUI, all had their incontinence 
resolved within three months. 46 men (88.5%) 
with tSUI had full resolution of incontinence 
within the first six weeks, while the remaining 
6 men (11.5%) resolved between six weeks and 
three months.
 Table-1 highlights preoperative ba-
seline characteristics as well as perioperati-
ve results. Except for pre-operative prosta-
te size (tSUI: 148.7±56.8mL, long-term SUI: 
98.0±50.1mL, no SUI: 92.2±50.6mL, p <0.0001), 
Table 1 - Baseline Characteristics, Preoperative, and Perioperative Data.
Patients with no 
SUI (n=528)
tSUI patients (n=52) Long-term SUI (n=9) p-value
Preoperative Data  
Age 70.6±8.5 72.0±8.9 65.6±5.7 0.1027
BMI 28.7±7.8 29.6±5.8 28.2±4.1 0.7026
Serum PSA (ng/mL) 10.03±47.45 6.7±7.4 9.0±7.1 0.9388
Prostate Size (mL) 92.2±50.6 148.7±56.8 111.6±48.5 <0.0001
Pre-Op Uroflow Peak Flow (mL/s) 8.6±9.9 14.7±23.5 11.5±10.8 0.0009
Pre-Op Uroflow Mean Flow (mL/s) 3.4±2.5 3.7±3.2 3.5±1.8 0.9367
Pre-Op Post Void Residual (mL) 238.8±249.2 297.0±298.1 185.2±112.3 0.3030
Pre-Op IPSS Results 19.7±8.5 17.9±9.8 19.4±5.8 0.5897
Pre-Op IPSS QOL Results 3.6±1.2 3.5±1.5 3.8±0.7 0.8231
Pre-operative Catheterization (N, %) 201 (38.1%) 37 (71.2%) 7 (77.8%) <0.0001
Perioperative Data  
Laser Energy Used (kJ) 339.3±190.4 514.4±151.4 434.3±145.8 <0.0001
Laser On Time (min) 118.7±72.8 163.5±89.7 174.2±67.4 0.0204
Resected Prostate Weight (g) 70.2±42.8 135.5±70.5 103.2±52.4 <0.0001
Post-Op Catheterization Time (days) 5.5±3.5 4.9±2.1 6.6±4.6 0.6139
Post-Op Uroflow Peak Flow (mL/s) 24.3±17.6 24.0±11.6 24.8±9.5 0.9926
Post-Op Uroflow Mean Flow (mL/s) 6.4±4.8 5.1±3.2 6.4±1.7 0.6384
Post-Op Post Void Residual (mL) 63.4±89.3 63.4±78.5 10.3±10.5 0.3414
Post-Op IPSS Results 6.8±5.9 9.5±8.3 16.7±11.4 0.0005
Post-Op IPSS QOL Results 1.1±1.4 1.8±1.4 2.4±2.0 0.0214
Continuous data is presented as mean ± standard deviation; categorical data as proportions
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pre-operative Qmax (tSUI: 14.7±23.5mL/s, long-
-term SUI: 11.5±10.8mL/s, no SUI: 8.6±9.9mL/s, 
p=0.0009) and pre-operative catheter dependence 
(tSUI: 71.2% vs. long-term SUI: 77.8% vs. no SUI: 
38.1%, p <0.0001), there was no significant diffe-
rence between men who developed transient SUI, 
long-term SUI, and those who did not.
 With regard to perioperative and posto-
perative results, patients who developed SUI were 
found to have greater laser energy used (tSUI: 
514.4±151.4 kJ vs. long-term SUI: 434.3±145.8 
kJ vs. no SUI :339.3±190.4 kJ, p <0.0001), longer 
laser “on” time (tSUI: 163.5±89.7 min, long-term 
SUI: 174.2±67.4 min, no SUI: 118.7±72.8 min, 
p=0.0204), larger resected prostate weight (tSUI: 
135.5±70.5g, long-term SUI: 103.2±52.4g, no 
SUI: 70.2±42.8g, p <0.0001), higher overall IPSS 
score (tSUI: 9.5±8.3, long term SUI: 16.7±11.4, 
no SUI: 6.8±5.9, p=0.0005) and IPSS QOL scores 
(tSUI: 1.8±1.4, long term SUI: 2.4±2.0, no SUI: 
1.1±1.4, p=0.0214).
 When patients with tSUI were stratified by 
preoperative prostate volume of >100g (n=44) or 
≤100g (n=8), 8 men (100%) with prostates ≤100g 
had the resolution of tSUI within 6 weeks. In the 
44 men with larger (>100g) prostates, 38 (86.3%) 
had the resolution of tSUI within 6 weeks, while 
the remaining 6 (13.6%) had the resolution betwe-
en 6 weeks to 3 months. There was not a statisti-
cal significance (p=0.2394) in recovery time when 
comparing larger prostates (>100g) to smaller 
prostates (≤100g).
 On multivariable logistic regression analy-
sis, we performed multiple analyses looking for 
predictive factors predisposing patients to any SUI 
(Supplementary Table-1.1), tSUI (Supplementa-
ry Table-1.2), and long-term SUI (Supplementa-
ry Table-1.3). Results showed that only resected 
prostate weight was a significant predictor of de-
veloping any SUI (HR 1.020, 95% CI 1.007-1.033, 
p <0.05) and tSUI (HR 1.019, 95% CI 1.006-1.032, 
p <0.05). There were no risk factors identified for 
long-term SUI patients.
DISCUSSION
 HoLEP has struggled to gain widespread 
adoption within the urology community due to a 
well-established steep learning curve, requiring up 
to 50 cases to become proficient (11, 13, 14) The 
potential development of tSUI has also been a li-
miting factor in its uptake. SUI, the involuntary 
leakage of urine, is distressing and has been sho-
wn to decrease the quality of life in patients (15). 
Patient distress likely plays a role in the avoidance 
of this prostate reducing technique by surgeons.
 In our study, we evaluated the inciden-
ce and predictors of SUI after HoLEP. We then 
looked to compare our results to those of other 
prostate reducing procedures in the literature. In 
patients undergoing TURP, the incidence of long-
-term stress incontinence is rare (~1%), although 
30-40% of patients have tSUI resolving within six 
months (16, 17). On the other hand, in men under-
going open simple prostatectomy (OP), there is a 
much higher incidence of long-term incontinence 
ranging between 1-40% depending on the tech-
nique utilized, with more current data showing 
20.2% of patients becoming permanently inconti-
nent (18-21). Further studies have shown a 38.6% 
incidence of tSUI in the three months following 
simple prostatectomy (22). In comparison, the in-
cidence of long-term and transient SUI in our sin-
gle-surgeon series is 1.5% and 8.8%, respectively. 
Our results suggest improved surgical outcomes 
compared to the published literature.
 Both HoLEP and simple prostatectomy 
seek to provide complete enucleation of the ade-
noma. Our HoLEP technique involves endoscopic 
dissection of the adenoma in a retrograde fashion, 
from the distal to the proximal attachments. Ho-
LEP allows for distal visualization of the adenoma, 
compared to the blind approach taken with OP. We 
feel that this visualization confers an advantage, 
as visual landmarks allow for the surgeon to avoid 
damage to the sphincter, and may play a role in 
lower incontinence rates seen in HoLEP versus OP.
 Variable tSUI rates after HoLEP have 
been reported in the literature. Previous studies 
have outlined this complication as occurring in 
anywhere from 1.4-44% of patients, of which the 
vast majority recover full continence by one year 
(10, 11, 23). A more recent large cohort study from 
Japan reported a tSUI rate after HoLEP of 16.6%, 
which is more consistent with our series (8). Ho-
wever, while the extreme variation in reported SUI 
IBJU | STRESS INCONTINENCE FOLLOWING HOLEP SURGERY
628
rates postoperatively is likely a function of small 
sample sizes, variable operative experience, he-
terogeneous operative techniques, and possible 
prior bladder dysfunction, our series has the ad-
vantage of being a large single-surgeon series. 
Shah et al. assessed the amount of time required 
to regain bladder control following HoLEP and 
found that it took 42.3 days (24). These results 
are consistent with our study, in which all pa-
tients who developed tSUI had complete a re-
covery by three months. We assessed if a larger 
prostate size was associated with rate of tSUI re-
covery. All six patients who took over 6 weeks 
to recover had large prostate volume, while no 
patients took over 6 weeks with a low prostate 
volume. Though the analysis did not show statis-
tical significance (p=0.2394), the absolute num-
bers suggest that men with larger prostate may 
have a slightly slower rate of recovery.
 This study also sought to uncover risk 
factors that may predispose patients to SUI, 
both transient and long-term. There was a sta-
tistical difference seen amongst the three groups 
on analysis for preoperative prostate size, pre-
operative Qmax, laser “on” time, laser energy 
used, and resected prostate volume. A novel fin-
ding of our study was the association of preo-
perative catheter dependence with postoperative 
incontinence. The cause of this correlation re-
mains unknown, but it is possible that patients 
requiring preoperative catheterization have 
more severe BPH, and therefore require longer 
endoscopic manipulation, which predisposes the 
patients to SUI. The only prior study looking 
at risk factors by Nam et al. identified increa-
sing age and operative time as risk factors (25). 
However, on our multivariate logistic regression 
analysis, only resected prostate weight was a 
significant predictor of developing any SUI (HR 
1.020, 95% CI 1.007-1.033, p <0.05) and tSUI 
(HR 1.019, 95% CI 1.006-1.032, p <0.05).
 Our study showed the rate of long-term 
incontinence to be very low. While no preoperati-
ve risk factors predisposing patients to long-term 
SUI were identified on multivariate regression, 
post-analysis chart review of these 9 patients un-
covered a high rate of neurological comorbidities. 
Further investigation showed that 8/9 (88.9%) 
patients had a significant neurological history. 
However, as we cannot accurately capture the in-
cidence of neurological comorbidities that exist 
within the rest of the population, a comparison 
was not possible. Of the 8, 7 had spinal patholo-
gy, including spinal stenosis and degenerative disc 
disease, while 1 had myasthenia gravis. Critically, 
all of these patients were able to achieve either 
complete resolution of SUI or reduction to less 
than 2 pads/day. The management strategies for 
these patients included initial pelvic floor exerci-
se therapy, and in those still unsatisfied, coaptite 
injections. Multiple coaptite injections were gi-
ven to patients who had partial responses. Only 
one patient went on to require AUS implantation. 
These 9 patients achieved a satisfactory level of 
continence at an average of 16.4 months after the 
completion of their HoLEP.
 When assessing postoperative QOL outco-
mes, we found that men with tSUI and long-term 
SUI had worse postoperative IPSS scores (both 
worse subjective symptoms and quality of life 
responses) when compared to those patients who 
did not experience tSUI. As expected, SUI had a 
substantial negative impact on quality of life. This 
result is in line with previous reports showing the 
quality of life impact that incontinence can have 
on patients (26).
 One possible cause of incontinence seen 
after surgery is sphincter dysfunction, which is 
likely the result of prolonged endoscopic mani-
pulation. Endoscopic procedures are thought to 
cause trauma directly to the sphincter, leading 
to this dysfunction. This dysfunction is thought 
to be temporary, causing the transient nature of 
the SUI (8, 11, 27) A larger prostate size leads to 
longer operative times, which may explain the 
correlation between tSUI and both larger prosta-
tes and longer operative times. The longer laser 
time and laser energy used, as well as the heavier 
weight of resected prostate tissue, are all asso-
ciated with a larger prostate. All of our results 
seem to indicate that larger prostates cause lon-
ger operations, and therefore increased endosco-
pic manipulation and risk for tSUI via sphincter 
dysfunction. As many of the variables associated 
with tSUI on univariate analysis were surrogate 
markers of prostate size, this may explain why 
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they were not independently associated with tSUI 
on multivariate regression analysis.
 This study is not devoid of limitations, 
including those inherent to a retrospective study. 
SUI characterization was primarily dependent on 
physician documentation. Missing data, especially 
from operative variables, also limited the robust-
ness of the multivariable analysis. Comorbidities, 
such as diabetes, that may have been associated 
with SUI development were not adequately captu-
red.
 Regardless of these limitations, this study 
still represents the largest single-surgeon expe-
rience with HoLEP and provided valuable data re-
garding the incidence, time course and predictors 
of post-operative tSUI. Transient SUI after HoLEP 
has notable implications for patient quality of life, 
which may contribute to the hesitancy in the wi-
despread adoption of HoLEP. Our study demons-
trates this tSUI resolves in the majority of patients, 
usually within the first six weeks. Furthermore, by 
identifying risk factors that predispose patients to 
tSUI, preoperative counseling can be enhanced, 
thus mitigating possible patient frustration and 
improving both patient and physician satisfaction. 
This may also provide data for better patient se-
lection in order to avoid these complications after 
the HoLEP procedure. We feel this study shows the 
need for future prospective trials and further in-
quiry into ways to prevent this complication.
CONCLUSIONS
 Overall, our study helps to highlight the 
relatively low rate of incontinence (10.4%) seen 
after HoLEP from an experienced surgeon, with 
8.8% being transient and 1.5% being long-term. 
Our results suggest that the overwhelming majori-
ty of patients with tSUI recover within the first 6 
weeks following HOLEP. Prostate size greater than 
100g and catheter dependency are associated with 
increased risk of developing tSUI, and larger pros-
tate volume is an independent predictor of tSUI. 
While long-term SUI was rare (1.5%), it is possible 
that neurologic complications may be a contri-
buting factor, though this requires further study. 
Those with long-term SUI are most often able to 
achieve continence with further intervention.
ABBREVIATIONS
SUI = Stress urinary incontinence
tSUI = Transient stress urinary incontinence
HoLEP = Holmium laser enucleation of prostate
BPH = Benign prostatic hyperplasia
LUTS = Lower urinary tract symptoms
TURP = Transurethral resection of prostate
PVR = Post-void residual
OP = Open prostatectomy
Qmax = Peak flow
IPSS = International prostate symptom score
QOL = Quality of life
PSA = Prostate-specific antigen
Fr = French
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Supplementary Table 1.1 - Results from multivariable logistic regression analysis assessing for risk factors for any SUI in 
HoLEP patients.
Variables OR (95% CI) p
Age (years) 0.981 (0.928-1.037) 0.494
BMI (Kg/m2) 0.983 (0.923-1.047) 0.597
Prostate Volume (mL) 1.009 (0.997-1.021) 0.133
Laser Energy Used (Kj) 0.990 (0.996-1.003) 0.763
Laser On Time (min) 0.997 (0.990-1.005) 0.463
Resected Prostate Volume (cc) 1.020 (1.007-1.033) 0.002
Supplementary Table 1.2 - Results from multivariable logistic regression analysis assessing for risk factors for tSUI 
in HoLEP patients.
Variables OR (95% CI) p
Age (years) 1.013 (0.949-1.083) 0.694
BMI (Kg/m2) 0.987 (0.925-1.054) 0.697
Prostate Volume (mL) 1.011 (0.997-1.025) 0.113
Laser Energy Used (Kj) 1.001 (0.996-1.006) 0.731
Laser On Time (min) 0.995 (0.986-1.004) 0.259
Resected Prostate Volume (cc) 1.019 (1.006-1.032) 0.004
Supplementary Table 1.3 - Results from multivariable logistic regression analysis assessing for risk factors for long-
term SUI in HoLEP patients.
Variables OR (95% CI) p
Age (years) 0.915 (0.825-1.014) 0.090
BMI (Kg/m2) 0.964 (0.830-1.120) 0.630
Prostate Volume (mL) 1.002 (0.978-1.026) 0.896
Laser Energy Used (Kj) 0.997 (0.990-1.003) 0.345
Laser On Time (min) 1.006 (0.994-1.019) 0.308
Resected Prostate Volume (cc) 1.009 (0.985-1.034) 0.456
